Varigenix™ Hepatocyte Panels for Early Toxicity Testing
June 22, 2011 - Unanticipated drug-induced toxicity is a major obstacle for drug development programs. Adverse reactions can halt development plans and end clinical trials. These reactions are often the result of individual patient genetic variation. Evaluating the effects of genetic variation on drug metabolism has become a critical aspect of early drug screening and an overall way to improve clinical success.
Overview of Varigenix™ Hepatocyte Panels
The Varigenix™ hepatocyte panels are a new tool set for studying the possible biologic effects of genetic variation. Characterized for genotypes and metabolic activity (ECOD), these panels express genetic variability comparable to human populations. They are comprised of cryopreserved BXD mouse hepatocytes with ≥80% post-thaw viability at one million cells/vial.
Application of Varigenix™ Hepatocyte Panels
The Varigenix™ hepatocyte panels make it possible to predict, prior to the start of clinical trials, the potential of human subpopulations to show drug toxicity. Among many biomedical uses, they allow for the evaluation of variation in drug metabolism, drug effectiveness, drug toxicity and environmental toxin interactions.
Four Panels to Choose From
(Note: only Panel 1 is available – others will be available based on market demand)
- Panels 1 & 2: Twenty-two male (Panel 1) or female (Panel 2) BXD strains selected from the BXD Taylor series of mouse lines: BXD1 to BXD42 and both parental strains which include C57BL/6J and DBA/2J.
- Panels 2 & 3: Twenty-two male (Panel 3) or female (Panel 4) BXD strains selected from the advanced BXD UTHSC series of mouse lines: BXD43 to BXD103 and both parental strains which include C57BL/6J and DBA/2J.
Additional Benefits
Varigenix™ hepatocyte panels are derived from the BXD family of mouse strains, which is the largest set of recombinant inbred mouse strains used for genetic analysis (as well as the most completely phenotyped). All of these strains are available for in vivo analysis and validation (and gene expression data can be openly accessed at www.genenetwork.org).
The genomes of the BXD strains used in Varigenix™ hepatocyte panels are genotyped at thousands of SNP markers and microsatellites. This makes it possible to map the potential genetic basis of drug and toxin responses and liver toxicity.
Discover the value of the Varigenix™ hepatocyte panels and their potential utility as a part of your drug development program by clicking here. For more information, please contact Rob Kaiser at robert.m.kaiser@crl.com or +919.462.8338.
Related Information